Skip to main content
. 2001 May 1;98(11):6372–6377. doi: 10.1073/pnas.091113598

Figure 1.

Figure 1

The NMDA antagonist dizocilpine (A) and the AMPA antagonist GYKI52466 (B) exert concentration-dependent antiproliferative effect in human tumor cell lines but not in human skin fibroblasts and bone marrow stromal cells. Cells were exposed to either culture medium alone (control), dizocilpine (1–250 μM), or GYKI52466 (1–250 μM) for 96 h, and viability was measured photometrically by means of the MTT assay. Data represent mean normalized optical densities ± SEM of 6–8 trials and were analyzed by means of linear regression. (C) Growth inhibition of neuroblastoma cells in three-dimensional cultures by dizocilpine (100–500 μM) is shown. Numbers of cells were assessed by counting, after trypsinization. ANOVA showed that the effect of treatment was significant [F(3,36) = 49.33, P < 0.001], with multiple comparisons revealing that dizocilpine induced antiproliferative action in a dose-dependent manner. The effect of time was also significant [F(4,36) = 296.69, P < 0.001], indicating that the antiproliferative effect of dizocilpine was more pronounced with time. SKNAS, human neuroblastoma; TE671, human rhabdomyosarcoma/medulloblastoma; MOGGCCM, human brain astrocytoma; FTC238, human thyroid carcinoma; A549, human Caucasian lung carcinoma; LS180, human Caucasian colon adenocarcinoma; T47D, human breast carcinoma; HT29, human colon adenocarcinoma; HSF, human skin fibroblasts; BMSC, human bone marrow stromal cells.